Tag: team

Ekopak (EKOP:xbru), a company specialized in circular water solutions, announces the appointment of Jean-Baptiste De Cuyper as its new CEO. This appointment follows the earlier communication of May 12, 2025, in which the company announced its intention to appoint an external candidate for this key role. The appointment is part of Ekopak's broader efforts to strengthen its governance and management structure.

Ekopak (EKOP:xbru), een onderneming gespecialiseerd in circulaire wateroplossingen, kondigt de benoeming aan van Jean-Baptiste De Cuyper als nieuwe CEO. Deze aanstelling volgt op de eerdere communicatie van 12 mei 2025 waarin het bedrijf haar intentie bekendmaakte om een externe kandidaat aan te stellen voor deze sleutelrol. De benoeming past binnen Ekopak’s bredere inspanningen om haar governance en managementstructuur te versterken.

London – 9 July 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary IgA nephropathy (IgAN).

Kert Keskpaik, previously a member of the Supervisory Board, has been appointed as its new Chairman. Tarmo Sild, who has chaired the Supervisory Board until now, will continue as a member of the Board.

“We have a team of people and outside counsel working around the clock to assess our options” - Shareholder Coalition

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.